Total number of shares and voting rights in Zealand Pharma at December 31, 2018

Copenhagen, December 28, 2018 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, in accordance with Section 10 of the Danish Statutory Order on Issuers’ Disclosure Obligations, announces the total number of shares and voting rights in the Company at the end of a calendar month during which there have been changes to its share capital.

In Company announcement No. 31 / 2018 of December 14, 2018, Zealand announced an increase in its share capital after the exercise of employee warrants. Following the announcement, the table below lists the total number of shares and voting rights in Zealand at December 31, 2018:

<table>
<thead>
<tr>
<th>Date</th>
<th>Number of shares (nominal value of DKK 1 each)</th>
<th>Share capital (nominal value in DKK)</th>
<th>Number of voting rights</th>
</tr>
</thead>
<tbody>
<tr>
<td>December 31, 2018</td>
<td>30,786,827</td>
<td>30,786,827</td>
<td>30,786,827</td>
</tr>
</tbody>
</table>

For further information, please contact:

Mats Blom, Executive Vice President and Chief Financial Officer
Tel.: +45 31 53 79 73, e-mail: mabl@zealandpharma.com

About Zealand Pharma A/S
Zealand Pharma A/S (Nasdaq Copenhagen and New York: ZEAL) (“Zealand”) is a biotechnology company focused on the discovery and development of innovative peptide-based medicines. More than 10 drug candidates invented by Zealand have advanced into clinical development, of which two have reached the market. Zealand’s current pipeline of internal product candidates focus on specialty gastrointestinal and metabolic diseases. Zealand’s portfolio also includes two clinical license collaborations with Boehringer Ingelheim.

Zealand is based in Copenhagen (Glostrup), Denmark. For further information about the Company’s business and activities, please visit www.zealandpharma.com or follow Zealand on LinkedIn or Twitter @ZealandPharma.